摘要
目的探讨改良FOLFOX7方案联合复方苦参、艾迪注射液对进展期胃癌患者CA125、CEA、IL-6、TGFβ1和硫化氢水平的影响及用药安全性分析。方法将医院2016年6月—2018年6月收治的78例进展期胃癌患者纳入至本次研究,依照数字随机表法将其分为对照组与观察组各39例,对照组给予改良FOLFOX7方案治疗,观察组则行改良FOLFOX7方案联合复方苦参、艾迪注射液治疗,比较两组患者治疗前后血清免疫功能、血清CEA、CA125、白细胞介素-6(IL-6)、转化生长因子β1(TGFβ1)以及硫化氢水平,统计不良反应情况,观察治疗效果。结果对照组患者的血清免疫功能水平显著低于观察组,对比差异有统计学意义(P<0.05)。对照组患者的血清CEA、CA125水平明显高于观察组,对比差异有统计学意义(P<0.05)。对照组患者的IL-6和TGFβ1水平高于观察组,硫化氢水平低于观察组,对比差异有统计学意义(P<0.05)。对照组患者的不良反应发生率41.03%(16/39)高于观察组15.38%(6/39),对比差异有统计学意义(P<0.05)。对照组患者治疗的总有效率87.18%(34/39)低于观察组97.44%(38/39),对比差异有统计学意义(P<0.05)。结论在进展期胃癌患者接受治疗时,采用改良FOLFOX7方案联合复方苦参、艾迪注射液的临床治疗效果较好,值得在临床治疗中推广。
Objective To investigate the effect of modified FOLFOX7 regimen combined with Compound Kushen Injectionand Aidi Injection on levels of CA125,CEA,IL-6,TGFβ1 and hydrogen sulfide in patients with advanced gastric cancer and the safety of medication.Methods Seventy-eight patients with advanced gastric cancer admitted to our hospital from June 2016 to June 2018 were included in the study.They were divided into control group(39 cases)and observation group(39 cases)according to the numerical random table method.The control group was treated with modified FOLFOX7 regimen.The observation group was treated with modified FOLFOX7 regimen combined with Compound Kushen Injectionand Aidi Injection.The serum immune function,serum levels of CEA,CA125,interleukin-6(IL-6),transforming growth factorβ1(TGFβ1)and hydrogen sulfide were compared before and after treatment.The toxic and side effects and the treatment effect were observed.Results The serum immune function level of the control group was significantly lower than that of the observation group,and the difference was statistically significant(P<0.05).Serum levels of CEA and CA125 in the control group were significantly higher than those in the observation group,and the difference was statistically significant(P<0.05).The levels of IL-6 and TGFβ1 in the control group were higher than those in the observation group,and the hydrogen sulfide level was lower than that in the observation group.The difference was statistically significant(P<0.05).The incidence of toxic and side effects in the control group was 41.03%(16/39),higher than that in the observation group 15.38%(6/39),and the difference was statistically significant(P<0.05).The total effective rate in the control group was 87.18%(34/39),lower than that in the observation group 97.44%(38/39),and the difference was statistically significant(P<0.05).Conclusion In the treatment of patients with advanced gastric cancer,the improved FOLFOX7 regimen combined with Compound Kushen Injectionand Aidi Injection has a good clinical
作者
孟祥云
孟汪洋
叶茜
戴丽
胡娟
汪星辉
李国辉
MENG Xiangyun;MENG Wangyang;YE Xi;DAI Li;HU Juan;WANG Xinghui;LI Guohui(Department of Pharmacy,The Second People’s Hospital of Hefei,Hefei 23000,Anhui,China;Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430030,Hubei,China;Cancer Hospital China Academy of Medical Sciences,Beijing 100200,China)
出处
《中华中医药学刊》
CAS
北大核心
2020年第7期208-211,共4页
Chinese Archives of Traditional Chinese Medicine
基金
北京市医卫健康公益基金会项目(GXYB-005)。
